240 related articles for article (PubMed ID: 32454027)
1. HIV-Resistant and HIV-Specific CAR-Modified CD4
Maldini CR; Gayout K; Leibman RS; Dopkin DL; Mills JP; Shan X; Glover JA; Riley JL
Mol Ther; 2020 Jul; 28(7):1585-1599. PubMed ID: 32454027
[TBL] [Abstract][Full Text] [Related]
2. Dual CD4-based CAR T cells with distinct costimulatory domains mitigate HIV pathogenesis in vivo.
Maldini CR; Claiborne DT; Okawa K; Chen T; Dopkin DL; Shan X; Power KA; Trifonova RT; Krupp K; Phelps M; Vrbanac VD; Tanno S; Bateson T; Leslie GJ; Hoxie JA; Boutwell CL; Riley JL; Allen TM
Nat Med; 2020 Nov; 26(11):1776-1787. PubMed ID: 32868878
[TBL] [Abstract][Full Text] [Related]
3. Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation.
Guedan S; Posey AD; Shaw C; Wing A; Da T; Patel PR; McGettigan SE; Casado-Medrano V; Kawalekar OU; Uribe-Herranz M; Song D; Melenhorst JJ; Lacey SF; Scholler J; Keith B; Young RM; June CH
JCI Insight; 2018 Jan; 3(1):. PubMed ID: 29321369
[TBL] [Abstract][Full Text] [Related]
4. HIV-1-Specific Chimeric Antigen Receptor T Cells Fail To Recognize and Eliminate the Follicular Dendritic Cell HIV Reservoir
Ollerton MT; Berger EA; Connick E; Burton GF
J Virol; 2020 May; 94(10):. PubMed ID: 32161179
[TBL] [Abstract][Full Text] [Related]
5. Supraphysiologic control over HIV-1 replication mediated by CD8 T cells expressing a re-engineered CD4-based chimeric antigen receptor.
Leibman RS; Richardson MW; Ellebrecht CT; Maldini CR; Glover JA; Secreto AJ; Kulikovskaya I; Lacey SF; Akkina SR; Yi Y; Shaheen F; Wang J; Dufendach KA; Holmes MC; Collman RG; Payne AS; Riley JL
PLoS Pathog; 2017 Oct; 13(10):e1006613. PubMed ID: 29023549
[TBL] [Abstract][Full Text] [Related]
6. Advances in Developing CAR T-Cell Therapy for HIV Cure.
Qi J; Ding C; Jiang X; Gao Y
Front Immunol; 2020; 11():361. PubMed ID: 32210965
[TBL] [Abstract][Full Text] [Related]
7. 4-1BB ligand induces cell division, sustains survival, and enhances effector function of CD4 and CD8 T cells with similar efficacy.
Cannons JL; Lau P; Ghumman B; DeBenedette MA; Yagita H; Okumura K; Watts TH
J Immunol; 2001 Aug; 167(3):1313-24. PubMed ID: 11466348
[TBL] [Abstract][Full Text] [Related]
8. Chimeric Antigen Receptor T Cells Guided by the Single-Chain Fv of a Broadly Neutralizing Antibody Specifically and Effectively Eradicate Virus Reactivated from Latency in CD4+ T Lymphocytes Isolated from HIV-1-Infected Individuals Receiving Suppressive Combined Antiretroviral Therapy.
Liu B; Zou F; Lu L; Chen C; He D; Zhang X; Tang X; Liu C; Li L; Zhang H
J Virol; 2016 Nov; 90(21):9712-9724. PubMed ID: 27535056
[TBL] [Abstract][Full Text] [Related]
9. CD8
Whittington KB; Prislovsky A; Beaty J; Albritton L; Radic M; Rosloniec EF
J Immunol; 2022 Jan; 208(1):16-26. PubMed ID: 34819392
[TBL] [Abstract][Full Text] [Related]
10. Generation of Anti-HIV CAR-T Cells for Preclinical Research.
Su H; Anthony-Gonda K; Orentas RJ; Dropulić B; Goldstein H
Methods Mol Biol; 2024; 2807():287-298. PubMed ID: 38743236
[TBL] [Abstract][Full Text] [Related]
11. Robust CAR-T memory formation and function via hematopoietic stem cell delivery.
Zhen A; Carrillo MA; Mu W; Rezek V; Martin H; Hamid P; Chen ISY; Yang OO; Zack JA; Kitchen SG
PLoS Pathog; 2021 Apr; 17(4):e1009404. PubMed ID: 33793675
[TBL] [Abstract][Full Text] [Related]
12. Bispecific chimeric antigen receptors targeting the CD4 binding site and high-mannose Glycans of gp120 optimized for anti-human immunodeficiency virus potency and breadth with minimal immunogenicity.
Ghanem MH; Bolivar-Wagers S; Dey B; Hajduczki A; Vargas-Inchaustegui DA; Danielson DT; Bundoc V; Liu L; Berger EA
Cytotherapy; 2018 Mar; 20(3):407-419. PubMed ID: 29306566
[TBL] [Abstract][Full Text] [Related]
13. Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptor-engineered T Cells.
Drent E; Poels R; Ruiter R; van de Donk NWCJ; Zweegman S; Yuan H; de Bruijn J; Sadelain M; Lokhorst HM; Groen RWJ; Mutis T; Themeli M
Clin Cancer Res; 2019 Jul; 25(13):4014-4025. PubMed ID: 30979735
[TBL] [Abstract][Full Text] [Related]
14. Toward T Cell-Mediated Control or Elimination of HIV Reservoirs: Lessons From Cancer Immunology.
Mylvaganam G; Yanez AG; Maus M; Walker BD
Front Immunol; 2019; 10():2109. PubMed ID: 31552045
[TBL] [Abstract][Full Text] [Related]
15. 4-1BB and optimized CD28 co-stimulation enhances function of human mono-specific and bi-specific third-generation CAR T cells.
Roselli E; Boucher JC; Li G; Kotani H; Spitler K; Reid K; Cervantes EV; Bulliard Y; Tu N; Lee SB; Yu B; Locke FL; Davila ML
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34706886
[TBL] [Abstract][Full Text] [Related]
16. ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells.
Guedan S; Chen X; Madar A; Carpenito C; McGettigan SE; Frigault MJ; Lee J; Posey AD; Scholler J; Scholler N; Bonneau R; June CH
Blood; 2014 Aug; 124(7):1070-80. PubMed ID: 24986688
[TBL] [Abstract][Full Text] [Related]
17. Glycosylphosphatidylinositol-Anchored Anti-HIV scFv Efficiently Protects CD4 T Cells from HIV-1 Infection and Deletion in hu-PBL Mice.
Ye C; Wang W; Cheng L; Li G; Wen M; Wang Q; Zhang Q; Li D; Zhou P; Su L
J Virol; 2017 Feb; 91(3):. PubMed ID: 27881659
[TBL] [Abstract][Full Text] [Related]
18. Antiviral effect and ex vivo CD4+ T cell proliferation in HIV-positive patients as a result of CD28 costimulation.
Levine BL; Mosca JD; Riley JL; Carroll RG; Vahey MT; Jagodzinski LL; Wagner KF; Mayers DL; Burke DS; Weislow OS; St Louis DC; June CH
Science; 1996 Jun; 272(5270):1939-43. PubMed ID: 8658167
[TBL] [Abstract][Full Text] [Related]
19. Cytotoxic activity of anti-mucin 1 chimeric antigen receptor T cells expressing PD-1-CD28 switch receptor against cholangiocarcinoma cells.
Supimon K; Sangsuwannukul T; Sujjitjoon J; Chieochansin T; Junking M; Yenchitsomanus PT
Cytotherapy; 2023 Feb; 25(2):148-161. PubMed ID: 36396553
[TBL] [Abstract][Full Text] [Related]
20. HIV-Specific CAR T Cells with CD28 or 4-1BB Signaling Domains Are Phenotypically and Functionally Distinct and Effective at Suppressing HIV and Simian Immunodeficiency Virus.
Cartwright EK; Pampusch MS; Rendahl AK; Berger EA; Coleman-Fuller N; Skinner PJ
Immunohorizons; 2022 Oct; 6(10):693-704. PubMed ID: 36220186
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
